HSBC analyst Rajesh Kumar downgraded Roche (RHHBY) to Hold from Buy with a price target of CHF 295, down from CHF 338. The perception of Roche as being relatively defensive, and the potential excitement around orforglipron, “makes the stock a crowded trade,” the analyst tells investors in a research note. The firm believes the stock’s catalysts have played out.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche price target lowered to CHF 286 from CHF 312 at Morgan Stanley
- Genentech announces CENTERSTONE trial data published in NEJM
- Trump Trade: Auto makers exempt from some U.S. tariffs
- Roche seeking U.S. tariff relief in direct talks with White House, Reuters says
- Roche Holding AG: Mixed Q1’25 Results and Strategic U.S. Investments Justify Hold Rating